Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -127.41% is 932% below its 5-year average of -12.35%, around the middle of its 5-year range (-246.76%–14.22%).
14.52% below its 12-month average of -111.25%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -123.72%.
NET PROFIT MARGIN
-127.41%
NET PROFIT MARGIN AVG TTM
-111.25%
NET PROFIT MARGIN AVG 3Y
-34.02%
NET PROFIT MARGIN AVG 5Y
-12.35%
NET PROFIT MARGIN AVG 10Y
1.20%
NET PROFIT MARGIN AVG 15Y
-21.01%
NET PROFIT MARGIN AVG 20Y
-13.14%
CURRENT VS TTM AVG
-14.52%
CURRENT VS 3Y AVG
-274.56%
CURRENT VS 5Y AVG
-931.89%
CURRENT VS 10Y AVG
-10743.78%
CURRENT VS 15Y AVG
-506.36%
CURRENT VS 20Y AVG
-869.71%
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-36302.86%
vs the sector median at left
Vanda Pharmaceuticals Inc.
Market Cap
$271.81M
Net Profit Margin
-127.41%
TTM Avg
-111.25%
3Y Avg
-34.02%
5Y Avg
-12.35%
Market Cap
$270.80M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$266.92M
Net Profit Margin
-1941.09%
TTM Avg
-1708.77%
3Y Avg
-990.85%
5Y Avg
-815.81%
Market Cap
$266.59M
Net Profit Margin
0.00%
TTM Avg
-1289.52%
3Y Avg
-1135.48%
5Y Avg
-755.61%
Market Cap
$265.78M
Net Profit Margin
-10994.73%
TTM Avg
-520.92%
3Y Avg
-360.66%
5Y Avg
-288.77%
Market Cap
$264.25M
Net Profit Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$280.37M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$262.92M
Net Profit Margin
-62.59%
TTM Avg
-99.90%
3Y Avg
-225.27%
5Y Avg
-207.41%
Market Cap
$281.54M
Net Profit Margin
0.00%
TTM Avg
-6.08%
3Y Avg
-1303.66%
5Y Avg
-1073.20%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. (VNDA) | $271.81M | -127.41% | -111.25% | -34.02% | -12.35% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $270.80M | 0.00% | 0.00% | 0.00% | 0.00% |
| Fate Therapeutics, Inc. (FATE)vs › | $266.92M | -1941.09% | -1708.77% | -990.85% | -815.81% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $266.59M | 0.00% | -1289.52% | -1135.48% | -755.61% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | -10994.73% | -520.92% | -360.66% | -288.77% |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $280.37M | 0.00% | 0.00% | 0.00% | 0.00% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | -62.59% | -99.90% | -225.27% | -207.41% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.54M | 0.00% | -6.08% | -1303.66% | -1073.20% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | 0.00% | 0.00% | -5482.65% | -3802.53% |
Operating Margin
-70.0%
Net Profit Margin
-127.4%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -123.72% |
| 2026-03-31 | -93.91% |
| 2025-12-31 | -246.76% |
| 2025-09-30 | -40.15% |
| 2025-06-30 | -51.73% |
| 2025-03-31 | -58.94% |
| 2024-12-31 | -9.24% |
| 2024-09-30 | -11.17% |
| 2024-06-30 | -8.95% |
| 2024-03-31 | -8.74% |
| 2023-12-31 | -5.30% |
| 2023-09-30 | 0.35% |
| 2023-06-30 | 3.30% |
| 2023-03-31 | 5.20% |
| 2022-12-31 | 10.64% |
| 2022-09-30 | 5.01% |
| 2022-06-30 | 4.00% |
| 2022-03-31 | -10.68% |
| 2021-12-31 | 10.41% |
| 2021-09-30 | 11.09% |
| 2021-06-30 | 14.22% |
| 2021-03-31 | 13.80% |
| 2020-12-31 | 12.11% |
| 2020-09-30 | 9.86% |
| 2020-06-30 | 14.01% |
| 2020-03-31 | 0.84% |
| 2019-12-31 | 6.92% |
| 2019-09-30 | 168.82% |
| 2019-06-30 | 19.52% |
| 2019-03-31 | -1.28% |
| 2018-12-31 | 19.53% |
| 2018-09-30 | 14.59% |
| 2018-06-30 | 9.74% |
| 2018-03-31 | 7.03% |
| 2017-12-31 | -4.15% |
| 2017-09-30 | -11.01% |
| 2017-06-30 | -3.65% |
| 2017-03-31 | -20.43% |
| 2016-12-31 | -1.58% |
| 2016-09-30 | -1.12% |
| 2016-06-30 | -12.82% |
| 2016-03-31 | -37.15% |
| 2015-12-31 | -46.46% |
| 2015-09-30 | -33.38% |
| 2015-06-30 | -19.53% |
| 2015-03-31 | -46.14% |
| 2014-12-31 | 453.60% |
| 2014-09-30 | -9.65% |
| 2014-06-30 | -198.63% |
| 2014-03-31 | -290.20% |
| 2013-12-31 | -86.79% |
| 2013-09-30 | -61.78% |
| 2013-06-30 | -37.01% |
| 2013-03-31 | -51.72% |
| 2012-12-31 | -80.42% |
| 2012-09-30 | -64.26% |
| 2012-06-30 | -95.57% |
| 2012-03-31 | -97.80% |
| 2011-12-31 | -65.99% |
| 2011-09-30 | -38.57% |
| 2011-06-30 | -18.05% |
| 2011-03-31 | 1.81% |
| 2010-12-31 | 28.36% |
| 2010-09-30 | 43.95% |
| 2010-06-30 | 15.43% |
| 2010-03-31 | 4.26% |
| 2009-12-31 | -203.12% |
| 2009-09-30 | 0.00% |
| 2009-06-30 | 0.00% |
| 2009-03-31 | 0.00% |
| 2008-12-31 | 0.00% |
| 2008-09-30 | 0.00% |
| 2008-06-30 | 0.00% |
| 2008-03-31 | -554.03% |
| 2007-12-31 | 0.00% |
| 2007-09-30 | 0.00% |
| 2007-06-30 | 0.00% |
| 2007-03-31 | 0.00% |
| 2006-12-31 | 0.00% |
| 2006-09-30 | 0.00% |
| 2006-06-30 | 0.00% |
| 2006-03-31 | 0.00% |
| 2005-12-31 | 0.00% |
| 2005-09-30 | 0.00% |
| 2005-06-30 | 0.00% |
| 2005-03-31 | 0.00% |
